The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Significance of CD44 expression in head and neck cancer: a systemic review and meta-analysis
Open accessAbstract
BACKGROUND: CD44 has been reported to be involved with tumor growth and metastasis and has also been implicated as a CSC marker in head and neck squamous cell cancer (HNSCC). However, the prognostic value of CD44 still remains controversial; hence, we investigated the correlation between CD44 and the clinicopathological features of HNSCC by meta-analysis. METHODS: A comprehensive search was performed using PubMed, ISI web of Science and China National Knowledge Infrastructure (CNKI) up to April 2013. Only studies with immunohistochemical staining of HNSCC were considered. Data on TNM classification, tumor grade, disease free survival and 3- or 5-year overall survival rate were extracted. RESULTS: Thirty studies with 2102 patients met the inclusion criteria for the meta-analysis. Fifteen studies used anti-pan-CD44 antibody, 9 used anti-CD44-v6 antibody, 2 used anti-CD44-v3 and 2 used anti-CD44s antibody, 1 used anti-CD44-v9, and 1 used anti-CD44-v6,-v3 and -v4-5 simultaneously. The total percentage of CD44 expression was 57.8%, with 49.3% in oral cancer patients, 66.4% in pharynx and 54.7% in larynx cancer patients expressing CD44. No significant correlation between clinical features and CD44 expression was revealed for oral cancer patients, but CD44 was shown to be associated with advanced T categories (larynx: RR = 1.33, 95% CI 1.01-1.76; larynx & pharynx RR = 1.21, 95% CI 1.08-1.35), worse N categories (larynx: RR = 2.53, 95% CI 1.99-3.21; larynx & pharynx RR = 1.95, 95% CI 1.35-2.82), higher tumor grades (larynx & pharynx RR = 1.71, 95% CI 1.04-2.79) and 5-year OS rates (larynx: RR = 0.62, 95% CI 0.47-0.83; larynx & pharynx RR = 0.66, 95% CI 0.47-0.94) in patients with laryngeal and pharyngolaryngeal cancer. In stratified analysis, pan-CD44 and CD44-v6 expression were both correlated with 5-year OS rate of patients with laryngeal (CD44: RR = 0.66, 95% CI 0.46-0.95; CD44-v6 RR = 0.53, 95% CI 0.37-0.77) and pharyngolaryngeal cancer (CD44: RR = 0.56, 95% CI 0.34-0.93; CD44-v6 RR = 0.53, 95% CI 0.37-0.77). CONCLUSIONS: Our analysis suggested that CD44 is related to worse T category, N category, tumor grade and prognosis, in pharyngeal and laryngeal cancer, but no clear association was revealed between CD44 expression and oral cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Organizing the cell cortex: the role of ERM proteins
Fehon, R. G., McClatchey, A. I., & Bretscher, A. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2866 · Cited by 1,044 · cited 1×
“This process is the initial step of cell migration called extravasation [12,17,18].”
Background
Cited by
CD44: A Multifunctional Mediator of Cancer Progression
Hassn Mesrati, M., Syafruddin, S. E., Mohtar, M. A., & Syahir, A. (2021) · Biomolecules · doi:10.3390/biom11121850 · Cited by 492
The Prognostic and Clinical Value of CD44 in Colorectal Cancer: A Meta-Analysis
Wang, Z., Tang, Y., Xie, L., Huang, A., Xue, C., Gu, Z., Wang, K., & Zong, S. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00309 · Cited by 100
Metadata
- Authors
- Chen, J., Zhou, J., Lu, J., Xiong, H., Shi, X., & Gong, L.
- Venue
- BMC Cancer
- Published
- 2014-01-13
- Volume
- 14
- Issue
- 1
- Pages
- 15-15
- ISSN
- 1471-2407 (ISSN-L)
- OpenAlex
- W2035989812
- Cited by
- 184
- References
- 2
- FWCI
- 12.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Significance of CD44 expression in head and neck cancer: a systemic review and meta-analysis. https://app.cochat.ai/papers/10.1186/1471-2407-14-15
- The paper
- Chen, J., Zhou, J., Lu, J., Xiong, H., Shi, X., & Gong, L. (2014). Significance of CD44 expression in head and neck cancer: a systemic review and meta-analysis. BMC Cancer. https://doi.org/10.1186/1471-2407-14-15
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.